开云app官网登录入口网页版-官方正版

#THORAC#

175篇内容 | 2773人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2057123, encodeId=1236205e1236f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=73, createdTime=2023-04-09, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057121, encodeId=4ab5205e1214f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=95, createdTime=2022-11-06, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057124, encodeId=bfaa205e124e4, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, objectType=article, longId=728905, objectId=5bbce28905b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bbce28905b8, replyNumber=0, likeNumber=92, createdTime=2022-10-17, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bbce28905b8, moduleTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5bbce28905b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057111, encodeId=5f34205e111fe, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响, objectType=article, longId=301403, objectId=2fa130140391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fa130140391, replyNumber=0, likeNumber=115, createdTime=2022-11-07, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa130140391, moduleTitle=J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2fa130140391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057114, encodeId=d396205e1142f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, objectType=article, longId=726424, objectId=b321e2642494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b321e2642494, replyNumber=0, likeNumber=78, createdTime=2022-08-25, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b321e2642494, moduleTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b321e2642494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057112, encodeId=4059205e11236, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, objectType=article, longId=301524, objectId=dfda301524c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfda301524c5, replyNumber=0, likeNumber=98, createdTime=2023-03-03, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfda301524c5, moduleTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dfda301524c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057113, encodeId=12f9205e11315, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化, objectType=article, longId=301646, objectId=b80230164678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b80230164678, replyNumber=0, likeNumber=95, createdTime=2022-12-11, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b80230164678, moduleTitle=J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b80230164678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057109, encodeId=5a4e205e109b0, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, objectType=article, longId=301255, objectId=1a8d30125528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a8d30125528, replyNumber=0, likeNumber=82, createdTime=2022-10-07, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a8d30125528, moduleTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1a8d30125528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057117, encodeId=669d205e117fa, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, objectType=article, longId=727473, objectId=6721e274735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6721e274735c, replyNumber=0, likeNumber=135, createdTime=2022-08-19, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6721e274735c, moduleTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6721e274735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057105, encodeId=804a205e105ba, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, objectType=article, longId=295185, objectId=293529518574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293529518574, replyNumber=0, likeNumber=102, createdTime=2022-12-30, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293529518574, moduleTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=293529518574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057125, encodeId=3e7d205e1255b, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, objectType=article, longId=727467, objectId=fe0ae2746739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0ae2746739, replyNumber=0, likeNumber=85, createdTime=2022-08-15, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0ae2746739, moduleTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe0ae2746739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057116, encodeId=2dcc205e116b4, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, objectType=article, longId=727595, objectId=086be27595c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=086be27595c5, replyNumber=0, likeNumber=86, createdTime=2023-02-22, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=086be27595c5, moduleTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=086be27595c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057100, encodeId=80ee205e1004e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, objectType=article, longId=293621, objectId=07a32936217f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07a32936217f, replyNumber=0, likeNumber=81, createdTime=2022-01-22, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07a32936217f, moduleTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=07a32936217f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057115, encodeId=14df205e115a6, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=78, createdTime=2022-07-27, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057122, encodeId=54db205e1224d, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Eur J Cardiothorac Surg：胸骨深部伤口感染局部应用庆大霉素并不会缩短患者住院时间，降低死亡率, objectType=article, longId=728144, objectId=2ce3e2814433, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ce3e2814433, replyNumber=0, likeNumber=88, createdTime=2022-11-07, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ce3e2814433, moduleTitle=Eur J Cardiothorac Surg：胸骨深部伤口感染局部应用庆大霉素并不会缩短患者住院时间，降低死亡率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2ce3e2814433)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057088, encodeId=8f83205e088f4, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=83, createdTime=2021-12-24, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057104, encodeId=d10c205e104f8, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol: 探索肺癌生存率性别差异的预后因素, objectType=article, longId=295171, objectId=8e7d2951e11a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7d2951e11a, replyNumber=0, likeNumber=92, createdTime=2023-01-20, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7d2951e11a, moduleTitle=J Thorac Oncol: 探索肺癌生存率性别差异的预后因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8e7d2951e11a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057110, encodeId=e0a9205e1105f, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, objectType=article, longId=301398, objectId=90fb30139881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90fb30139881, replyNumber=0, likeNumber=87, createdTime=2023-01-08, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90fb30139881, moduleTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=90fb30139881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057082, encodeId=199c205e0828a, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值, objectType=article, longId=218079, objectId=d7002180e97d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7002180e97d, replyNumber=0, likeNumber=77, createdTime=2022-01-12, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7002180e97d, moduleTitle=J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d7002180e97d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2057098, encodeId=d442205e09805, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=107, createdTime=2022-07-30, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

THORAC

2020-05-29

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2023-04-09

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-11-06

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效

2022-10-17

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响

2022-11-07

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效

2022-08-25

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效

2023-03-03

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化

2022-12-11

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效

2022-10-07

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

2022-08-19

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性

2022-12-30

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效

2022-08-15

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果

2023-02-22

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素

2022-01-22

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2022-07-27

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Eur J Cardiothorac Surg：胸骨深部伤口感染局部应用庆大霉素并不会缩短患者住院时间，降低死亡率

2022-11-07

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2021-12-24

智慧医人 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol: 探索肺癌生存率性别差异的预后因素

2023-01-20

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效

2023-01-08

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

J Thorac Oncol：综合分析TP53和KEAP1突变在非小细胞肺癌(NSCLC)中的预后价值

2022-01-12

yyj062 (审核中...)

前往app查看评论内容

#THORAC#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2022-07-30

科室
- - 订阅+
  - 更多科室
工具
服务